tert-butyl 4-{[(2,4-difluorophenyl)methyl]amino}piperidine-1-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-{[(2,4-difluorophenyl)methyl]amino}piperidine-1-carboxylate
• 英文别名: tert-Butyl 4-(2,4-difluorobenzylamino)piperidine-1-carboxylate；tert-butyl 4-[(2,4-difluorophenyl)methylamino]piperidine-1-carboxylate
• 化学式: C₁₇H₂₄F₂N₂O₂
• 分子量: 326.387
• InChiKey: MZARIHVKFYHWHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-{[(2,4-difluorophenyl)methyl]amino}piperidine-1-carboxylate 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 1-[(2,4-difluorophenyl)methyl]-3-[(2,2-dimethyl-2,3-dihydro-1-benzofuran-5-yl)methyl]-1-(piperidin-4-yl)urea trifluoroacetic acid salt
  参考文献：
  名称：

  [EN] COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES
  [FR] COMPOSÉS, SELS CORRESPONDANTS ET MÉTHODES POUR LE TRAITEMENT DE MALADIES

  摘要：

  本公开涉及按照式（I）的化合物，用于治疗疾病。

  公开号：

  WO2019040107A1
• 作为产物：
  描述：

  2,4-二氟苄胺 、 N-叔丁氧羰基-4-哌啶酮 在 乙醇 、 三乙酰氧基硼氢化钠 作用下， 反应 2.0h， 生成 tert-butyl 4-{[(2,4-difluorophenyl)methyl]amino}piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES
  [FR] COMPOSÉS, SELS CORRESPONDANTS ET MÉTHODES POUR LE TRAITEMENT DE MALADIES

  摘要：

  本公开涉及按照式（I）的化合物，用于治疗疾病。

  公开号：

  WO2019040107A1

文献信息

• Compounds, salts thereof and methods for treatment of diseases
  申请人：ACADIA PHARMACEUTICALS INC.

  公开号：US11345693B2

  公开（公告）日：2022-05-31

  The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

  本公开涉及可用于治疗疾病的式 (I) 化合物。
• [EN] 5-HT2A RECEPTOR ANTAGONIST AND APPLICATION THEREOF IN TREATING CENTRAL NERVOUS SYSTEM DISEASES<br/>[FR] ANTAGONISTE DU RÉCEPTEUR 5-HT2A ET SON APPLICATION DANS LE TRAITEMENT DE MALADIES DU SYSTÈME NERVEUX CENTRAL<br/>[ZH] 5-HT2A受体拮抗剂及其治疗中枢神经系统疾病的应用
  申请人：HAN YUAN MEDI PHARM CO LTD

  公开号：WO2021147818A1

  公开（公告）日：2021-07-29

  一种具有中枢神经系统疾病治疗作用的式I结构的化合物，其具有5-HT2A受体拮抗剂或反向激动剂活性，并且对5-HT2A受体的选择性高、心脏毒性低、代谢稳定性好，可以用于治疗某些精神疾病(如抑郁症、焦虑症、精神病、精神分裂症、失眠、自闭症)及与中枢神经系统退行性疾病(如阿尔兹海默症、帕金森病、亨廷顿病、路易小体痴呆症)相关或者并发的精神紊乱症状。
• COMPOUNDS, SALTS THEREOF AND METHODS FOR TREATMENT OF DISEASES
  申请人：Acadia Pharmaceuticals Inc.

  公开号：EP3672954A1

  公开（公告）日：2020-07-01
• Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
  申请人：Aslanian G. Robert

  公开号：US20070015807A1

  公开（公告）日：2007-01-18

  Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M 1 and M 3 are CH or N; M 2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH 2 ) q —, —C(═NOR 7 )— or —SO 1-2 —; Z is a bond or optionally substituted alkylene or alkenylene; R 1 is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula: where ring A is a heteroaryl ring; R 2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R 3 is H, —C(O)NH 2 , or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with other agents.
• HETEROATOM-LINKED SUBSTITUTED PIPERIDINES AND DERIVATIVES THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS
  申请人：Aslanian Robert G.

  公开号：US20090286830A1

  公开（公告）日：2009-11-19

  Disclosed are novel compounds of the formula or a pharmaceutically acceptable salt thereof, wherein: M 1 and M 3 are CH or N; M 2 is CH, CF or N; Y is —C(═O)—, —C(═S)—, —(CH 2 ) q —, —C(═NOR 7 )— or —SO 1-2 —; Z is a bond or optionally substituted alkylene or alkenylene; R 1 is H, or alkyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl, all optionally substituted, or a group of the formula: where ring A is a heteroaryl ring; R 2 is optionally substituted alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl; R 3 is H, —C(O)NH 2 , or alkyl, aryl, cycloalkyl, heterocycloalkyl or heteroaryl, all optionally substituted; and the remaining variables are as defined in the specification; compositions and methods of treating allergy-induced airway responses, congestion, obesity, metabolic syndrome, alcoholic fatty liver disease, hepatic steatosis, nonalcoholic steatohepatitis, cirrhosis, hepatacellular carcinoma and cognition deficit disorders using said compounds, alone or in combination with other agents.